Following recent patent approvals in the United States and China, Tissuemed is pleased to announce that within the last month the European Patent Office (EPO) has issued Notices of Allowance for 2 key patent applications covering Tissuemed’s novel bioadhesive polymer, TissueBond and the TissuePatch product family, incorporating TissuePatch and TissuePatchDural.
Tissuemed’s CEO, David Mandley commented, “Tissuemed is committed to protecting our novel and innovative technology There are some excellent claims within these 2 applications and this latest news from the EPO takes us closer to securing additional patent approvals in the European market”
For further information about the TissuePatch product family and potential collaborative opportunities contact Tissuemed at info@tissuemed.com